Cellular Biomedicine Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

Cellular Biomedicine Group, Inc. (CBMG), is a clinical-stage biopharmaceutical company. The Company is leveraging its cell-based technologies to develop immunotherapies for the treatment of cancer and stem cell therapies for the treatment of degenerative diseases. The Company provides comprehensive and integrated research and manufacturing services throughout the discovery, development and manufacturing spectrum for cell-based technologies. The Company's primary focus has been to serve the growing health care market initially in China by marketing and commercializing immune cell and stem cell therapeutics, related tools and products. The Company's treatment focal points are cancer and Knee Osteoarthritis (KOA). It is focusing its clinical development efforts on assets such as C-CAR088, C-CAR039, TIL051, AFT-TCRT in China and/or United States. It has also completed a Phase-I/IIa clinical study, in China, for our KOA therapy named ReJoin.